The primary objective was to assess non-inferiority [ per-protocol ( PP ) population ] , and then superiority [ intention-to-treat ( ITT ) population ] , of LM25 versus IGL according to change in HbA1c after 24 weeks ( non-inferiority margin 0.4 % , two-sided significance level 0.05 ) .